The collaborative consortium took on the challenging task of producing and integrating multi-omics datasets generated from key clinical sepsis pathogens from Australia and globally, to support discovery and translational research to tackle the global challenge in the rise of antimicrobial resistance.
Bioplatforms is committed to supporting the Australian life sciences community through a diverse access program, provision of targeted infrastructure requirements, and making integrated capability available to initiatives of breadth, scale and complexity in a way that is not readily achievable through other mechanisms.
Health and medical researchers investigate solutions to complex problems that are often not easily solved by a single discipline. The NCRIS Health Group is aimed at enabling them collaboratively throughout the innovation and translational process.
Bioplatforms Australia welcomes the recent announcement of the $185 million investment to fast-track treatments for rare and ‘untreatable’ cancers.
Bioplatforms Australia is seeking innovative ideas from current and potential future partners to identify opportunities to deepen and enhance the overall capability and capacity of its network.
The Bioplatforms Australia Plant Pathogen ‘Omics Initiative is now seeking partners to nominate and lead projects that will generate important genomic data resources for priority plant pathogen species.
The Woylie reference genome, and subsequent population genetic data, were used to inform the translocations of 54 Woylies into Mallee Cliffs National Park in NSW.
Since 2004, NCRIS has enabled a wealth of research excellence, making it both headline worthy and a critical pillar of the Australian economy. Leading economists agree.